Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood clot protein may reveal Cancer's next move

NCT ID NCT02304978

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a protein called tissue factor (TF) in the blood can help predict how serious colorectal cancer is and if it might come back. Researchers measured TF levels in 26 adults before and after surgery to remove their tumors. The goal was to see if higher TF levels are linked to more aggressive cancer and if levels drop after successful surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

26 people

The number who actually took part.

Started

Jun 2009

Finished

May 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients, adults, holders of CRC with or without MH in whom surgical resection HEALING is planned . For witnesses: \- Patients without CCR (preoperative colonoscopy). This control population will verify normal values regulators of angiogenesis recently defined and specificity of these vis-à-vis markers CCR- Exclusion Criteria: all situations where the plasma levels of FT antigen are high, in particular: * Patients with unstable angina or myocardial infarction in the acute phase (not older than two months) * Severe sepsis (hospitalization) * Cirrhosis stage Child C * Chronic renal failure requiring renal replacement extra * Patients with microvascular complications of diabetes * Vasculitis * Pregnancy and lactation patient on oral contraceptives, or having hormone replacement therapy for menopause * Patients with extrahepatic metastases * Patients underwent emergency surgery * Persons not able to consent For witnesses: History of cancer, inflammatory disease, diabetes, regular intake of anti inflammatory drugs. If during colonoscopy, colorectal cancer was detected, the control patients were excluded from the study -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

Contacts and locations

Locations

  • Service de Chirurgie Digestive et de transplantation Hôpital Claude HURIEZ

    Lille, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.